The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
This scoping review examined the relationship between glucagon-like peptide-1 receptor agonists (GLP-1RAs) — a class of medications used for type 2 diabetes and weight management — and hair loss (alopecia). Researchers searched PubMed for relevant articles published through April 2026. The review found conflicting evidence overall: some data suggested an association between GLP-1RA use (particularly semaglutide and tirzepatide) and telogen effluvium (a stress-related, diffuse hair shedding) as well as androgenic alopecia, with risk potentially tied to longer treatment duration, greater magnitude of weight loss, and higher doses. Proposed biological mechanisms included weight loss-induced physiological stress, changes in dermal white adipose tissue, and hormonal shifts, though the authors note their relative contributions remain poorly understood. Conversely, a smaller subset of literature indicated possible improvement in inflammatory forms of alopecia, especially in patients with underlying metabolic dysfunction. Key limitations include the scoping design's reliance on heterogeneous existing literature, absence of original clinical trial data, and the difficulty of disentangling drug effects from weight-loss effects. The authors conclude that dermatology practitioners should be aware of this association and consider patient counseling and monitoring.
Why this grade: This is a scoping review synthesizing existing literature without original primary data collection, so evidence strength is inherently dependent on the quality and consistency of the underlying sources reviewed.
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an increasingly prescribed class of antidiabetic medications with expanded use in chronic weight management. Emerging literature has raised concerns regarding dermatologic adverse effects of GLP-1RAs, including various forms of alopecia. Objective To evaluate the prevalence of GLP-1RA-associated alopecia, differences among agents, and proposed underlying mechanisms. Materials and methods A scoping review of GLP-1RAs and alopecia was conducted using PubMed, including articles published up to April 2026. Results Current literature presents conflicting evidence regarding the effects of GLP-1RAs on hair loss. Available data suggest an association between GLP-1RAs and telogen effluvium and androgenic alopecia, with risk potentially increasing with longer duration of use, greater weight loss, and higher doses, particularly with tirzepatide and semaglutide. Proposed mechanisms include weight loss-related changes, alterations in dermal white adipose tissue, and hormonal influences, although their relative contributions remain unclear. Conversely, a smaller body of literature suggests improvement in inflammatory alopecia with GLP-1RA use, particularly among patients with metabolic dysfunction. Conclusion Given the increasing use of GLP-1RAs, dermatology practitioners should be aware of their association with alopecia and consider patient counseling, monitoring, and proactive treatment in patients receiving GLP-1RA therapy.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.